Fisetin, a plant pigment sold as a dietary supplement, is promoted to clear worn-out cells that build up with age and inflame tissue. It removed such cells in mice, but in people short high-dose courses did not improve joint function, bone or infection outcomes in early studies, and no study has yet shown cell clearing. Short courses appear mostly well tolerated; effects on other medicines are a key concern. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Interleukin-6 | No established target; track change from own baseline | Inflammation signal |
| Fasting glucose | 70–99 mg/dL | Safety check with glucose-lowering drugs |
| Fasting insulin | Not specified in the ER | Metabolic baseline; paired with fasting glucose |
| HOMA-IR | No established target; track change from own baseline | Insulin resistance |
| ALT | 7–55 U/L | Liver safety: stop if above twice the upper normal limit |
| AST | Not specified in the ER | Liver safety; paired with ALT |
| Creatinine | 0.74–1.35 mg/dL men, 0.59–1.04 mg/dL women | Safety check: kidney clearance |
| INR | No established target; track against the prescriber-set warfarin range | Warfarin users only: possible raised warfarin effect |
| T-cell p16INK4a | No established target; research assay only | Senescent-cell burden |
| Six-minute walk distance | Not specified in the ER | Frailty-related function baseline |
| Grip strength | Not specified in the ER | Frailty-related function baseline |
| Chair-rise time | Not specified in the ER | Frailty-related function baseline |
Cadence: Baseline before the first pulse; safety labs 1–2 weeks after the first pulse, then every 3–6 months while cycling; inflammation and metabolic markers at 3 and 6 months; INR 3–7 days after each pulse for warfarin users.